NRX Pharmaceuticals Files 8-K

Ticker: NRXPW · Form: 8-K · Filed: May 13, 2025 · CIK: 1719406

Nrx Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyNrx Pharmaceuticals, INC. (NRXPW)
Form Type8-K
Filed DateMay 13, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financial-reporting

TL;DR

NRX Pharma filed an 8-K on 5/13/25, mostly procedural stuff and old name change info.

AI Summary

On May 13, 2025, NRX Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. The company was formerly known as Big Rock Partners Acquisition Corp. until a name change on October 12, 2017.

Why It Matters

This 8-K filing provides an update on NRX Pharmaceuticals' corporate activities and financial reporting, which is important for investors to monitor company status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting procedural information and historical data, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for NRX Pharmaceuticals, Inc.?

The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating routine corporate updates and financial reporting.

When was NRX Pharmaceuticals, Inc. previously known by another name?

The company was formerly known as Big Rock Partners Acquisition Corp. until October 12, 2017.

What is the state of incorporation for NRX Pharmaceuticals, Inc.?

NRX Pharmaceuticals, Inc. is incorporated in Delaware.

What is the principal executive office address for NRX Pharmaceuticals, Inc.?

The principal executive office is located at 1201 Orange Street, Suite 600, Wilmington, Delaware 19801.

What is the SIC code for NRX Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code is 2834 for Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding NRX Pharmaceuticals, Inc. (NRXPW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing